Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*-Reference-Cited by-同舟云学术

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*

Published:2009-07-08 Issue:8 Volume:25 Page:2081-2090
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Sheng Duh Mei¹,Dial Ellison¹,Choueiri Toni K.²,Fournier Andree-Anne¹,Antras Lucia¹,Rodermund Douglas¹,Neary Maureen P.³,Oh William K.²

Affiliation:

1. Analysis Group, Inc., Boston, MA, USA

2. Dana-Farber Cancer Institute, Boston, MA, USA

3. GlaxoSmithKline, Collegeville, PA, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/03007990903084800

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis;International Journal of Molecular Sciences;2023-06-15

2. Endoplasmic Reticulum Stress Activation in Alport Syndrome Varies Between Genotype and Cell Type;Frontiers in Genetics;2020-02-10

3. Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2019-06-21

4. Cost and cost-effectiveness studies in urologic oncology using large administrative databases;Urologic Oncology: Seminars and Original Investigations;2018-04

5. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database;Current Medical Research and Opinion;2017-08-07